Advertisement
Dr. Kiev, a peak performance strategist and author of six books on tradingpsychology, will speak on "Risk-Reward and Valuation of Clinical StageCompounds: Challenge Your Perspective." His presentation will coverinvestors' perceptions of early stage companies, advising biotech CEOs on themost effective ways to position clinical trial data to help achieve an optimumvaluation.
Advertisement
"Biotech CEOs should challenge their perspectives on the industry and tryto see valuation from an investor's point of view rather than that of ascientist," Dr. Kiev said. "There tends to be too much emphasis on hyperboleas to the novelty of the mechanism and the size of the market. Focusing toomuch on why the stock is going up or down can turn off investors who arelooking for greater involvement by the company in the path to success inclinical trials."
Dr. Kiev founded SPRI (www.spriclinicaltrials.com) in 1970 to provide toprate clinical trial services to the pharmaceutical and biotech industry. Withnearly 40 years of experience managing studies in the New York area, SPRIexpanded internationally in 2003. Today, the company conducts studiesthroughout Eastern and Western Europe.
SOURCE SPRI Clinical Trials
